Defence Arranges Financing
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) has announced a non-brokered private placement to raise up to $4.2 million through the issuance of up to 7 million units at $0.60 per unit. Each unit consists of one common share and one warrant, with each warrant allowing the purchase of an additional common share at $0.75 for 24 months after closing.
The proceeds will be used to advance preclinical and clinical programs and for general working capital. The company may pay finder's fees, and securities will be subject to a four-month and one-day hold period following closing.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) ha annunciato un collocamento privato non interbancato per raccogliere fino a 4,2 milioni di dollari tramite l'emissione di un massimo di 7 milioni di unit脿 a 0,60 dollari ciascuna. Ogni unit脿 猫 composta da un'azione ordinaria e un warrant, con ciascun warrant che consente l'acquisto di un'ulteriore azione ordinaria a 0,75 dollari per 24 mesi dopo la chiusura.
I proventi saranno utilizzati per far avanzare programmi preclinici e clinici e per il capitale di lavoro generale. L'azienda potrebbe pagare commissioni ai procacciatori, e i titoli saranno soggetti a un periodo di blocco di quattro mesi e un giorno dopo la chiusura.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) ha anunciado una colocaci贸n privada no mediada para recaudar hasta 4,2 millones de d贸lares mediante la emisi贸n de hasta 7 millones de unidades a 0,60 d贸lares por unidad. Cada unidad consta de una acci贸n ordinaria y un warrant, con cada warrant que permite la compra de una acci贸n ordinaria adicional a 0,75 d贸lares durante 24 meses despu茅s del cierre.
Los ingresos se utilizar谩n para avanzar en programas precl铆nicos y cl铆nicos y para el capital de trabajo general. La empresa puede pagar comisiones a agentes, y los valores estar谩n sujetos a un per铆odo de retenci贸n de cuatro meses y un d铆a despu茅s del cierre.
Defense Therapeutics (CSE: DTC) (OTCQB: DTCFF)電� 欷戧皽鞛� 鞐嗠姅 靷 氚办箻毳� 氚滍憸頃橃棳 斓滊寑 420毵� 雼煬毳� 氇笀頃橁赴 鞙勴暣 0.60 雼煬鞐� 斓滊寑 700毵� 臧滌潣 鞙犽嫑鞚� 氚滍枆頃� 鞓堨爼鞛呺媹雼�. 臧� 鞙犽嫑鞚� 氤错喌欤� 頃� 欤检檧 鞕�霟绊姼 頃橂倶搿� 甑劚霅橂┌, 臧� 鞕�霟绊姼電� 膦呺 頉� 24臧滌洈 霃欖晥 0.75 雼煬鞐� 於旉皜 氤错喌欤� 甑Г毳� 項堨毄頃╇媹雼�.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) a annonc茅 un placement priv茅 sans courtier pour lever jusqu'脿 4,2 millions de dollars par l'茅mission de jusqu'脿 7 millions d'unit茅s au prix de 0,60 $ par unit茅. Chaque unit茅 se compose d'une action ordinaire et d'un bon de souscription, chaque bon permettant d'acheter une action ordinaire suppl茅mentaire 脿 0,75 $ pendant 24 mois apr猫s la cl么ture.
Les fonds seront utilis茅s pour faire avancer les programmes pr茅cliniques et cliniques ainsi que pour le fonds de roulement g茅n茅ral. La soci茅t茅 peut payer des commissions de recherche, et les valeurs mobili猫res seront soumises 脿 une p茅riode de blocage de quatre mois et un jour apr猫s la cl么ture.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) hat eine nicht vermittelte Privatplatzierung angek眉ndigt, um bis zu 4,2 Millionen US-Dollar durch die Ausgabe von bis zu 7 Millionen Einheiten zu einem Preis von 0,60 US-Dollar pro Einheit zu beschaffen. Jede Einheit besteht aus einer Stammaktie und einem Warrant, wobei jeder Warrant den Kauf einer zus盲tzlichen Stammaktie zu 0,75 US-Dollar f眉r 24 Monate nach Abschluss erm枚glicht.
Die Einnahmen werden verwendet, um pr盲klinische und klinische Programme voranzutreiben und f眉r das allgemeine Betriebskapital. Das Unternehmen kann Vermittlungsprovisionen zahlen, und die Wertpapiere unterliegen nach dem Abschluss einer Haltedauer von vier Monaten und einem Tag.
- Secured potential funding of up to $4.2 million to advance clinical programs
- Warrant structure provides potential for additional future capital at $0.75 per share
- Dilutive effect on existing shareholders through issuance of up to 7 million new units
- Offering price of $0.60 per unit may represent a discount to market price
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce a non-brokered private placement of up to
Each Unit is comprised of one common share in the capital of the Company and one common share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one additional common share at a price of
The Company intends to use the net proceeds to advance its preclinical and clinical programs, and for general working capital. The Company may pay a finder's fee in connection with the Offering in accordance with the policies of the CSE. The securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day following the closing date in accordance with the CSE.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
FAQ
How much is Defence Therapeutics (DTCFF) raising in its private placement?
What are the terms of the DTCFF warrants in the December 2024 offering?
How will Defence Therapeutics use the proceeds from its $4.2M private placement?
What is the holding period for securities issued in Defence Therapeutics' private placement?
